Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats

Jenny Ahlqvist, Ruben Isacson, Claes R Wahlestedt, Peter Salmi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.

Original languageEnglish
Pages (from-to)177-182
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume13
Issue number3
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

olanzapine
Raclopride
Catalepsy
Clozapine
Dopamine D1 Receptors
Antipsychotic Agents
Substance-Induced Psychoses
Pharmacology
SCH 23390
Quetiapine Fumarate

Keywords

  • Atypical antipsychotics
  • Catalepsy
  • Clozapine
  • Olanzapine
  • Parkinson's disease
  • Quetiapine

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. / Ahlqvist, Jenny; Isacson, Ruben; Wahlestedt, Claes R; Salmi, Peter.

In: European Neuropsychopharmacology, Vol. 13, No. 3, 01.05.2003, p. 177-182.

Research output: Contribution to journalArticle

@article{59c5d6895bdb4865a5eeb4bd58b35d16,
title = "Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats",
abstract = "The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.",
keywords = "Atypical antipsychotics, Catalepsy, Clozapine, Olanzapine, Parkinson's disease, Quetiapine",
author = "Jenny Ahlqvist and Ruben Isacson and Wahlestedt, {Claes R} and Peter Salmi",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0924-977X(03)00004-X",
language = "English",
volume = "13",
pages = "177--182",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats

AU - Ahlqvist, Jenny

AU - Isacson, Ruben

AU - Wahlestedt, Claes R

AU - Salmi, Peter

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.

AB - The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg-1, s.c.), but not olanzapine (2.0 mg kg-1, s.c.) and quetiapine (20.0 mg kg-1, s.c.), blocked catalepsy induced either by the dopamine D1/5 receptor antagonist SCH 23390 (50.0 μg kg-1, s.c) or the selective dopamine D2/3 receptor antagonist raclopride (4.0 mg kg-1, s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D1 receptor agonism of clozapine.

KW - Atypical antipsychotics

KW - Catalepsy

KW - Clozapine

KW - Olanzapine

KW - Parkinson's disease

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=0037406047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037406047&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(03)00004-X

DO - 10.1016/S0924-977X(03)00004-X

M3 - Article

VL - 13

SP - 177

EP - 182

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 3

ER -